After working with a number of leading pharmaceutical companies in the US, Anna Richo joined international biopharmaceutical firm UCB in Brussels, Belgium, in 2012. As UCB’s executive vice president and general counsel, Anna Richo is responsible for the legal, corporate compliance, and intellectual property departments at UCB.
Focused on creating treatments for immunology and central nervous system disorders, UCB engages in an extensive and complicated drug development process that can span between 10 and 12 years. UCB explains that it costs more than 800 million pounds to fully develop a new drug, with approximately 60 percent of that cost dedicated to rigorous clinical trials. During the clinical development process, UCB conducts three trial phases that involve an increasing number of patients in order to explore drug efficacy, safety, and side effects. According to the company, new drugs are chosen from thousands of substances that could potentially treat a certain condition, but for a wide range of reasons, fewer than one or two substances per 10,000 analyzed succeed in reaching the market with authorization for patient use.
0 Comments
|
AuthorAs of November 1, 2012, Anna Richo became Executive Vice President and General Counsel of UCB, a biopharmaceutical company headquartered in Brussels, Belgium. Archives
August 2018
Categories
All
|